Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study
Haemophilia · 2026-01 · 32 (1) · 63-70
DOI: 10.1111/hae.70151 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Haemophilia, online erschienen am 11.11.2025. Verfasst von Tyler W Buckner und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado School of Medicine, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Hemophilia A, Antibodies, Bispecific, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Genentech, Inc.
Abstract (Originalsprache)
Background
The Natural History Study of the Safety, Effectiveness, and Practice of Treatment for People with Haemophilia (ATHN 7) monitors use of contemporary haemophilia therapies, including emicizumab, a bispecific antibody substituting for activated factor (F)VIII in people with haemophilia A (HA).
Aim
To report participant characteristics and real‐world safety and effectiveness of emicizumab in ATHN 7.
Methods
ATHN 7 is a prospective observational cohort study conducted across 26 American Thrombosis and Haemostasis Network (ATHN)‐affiliated sites. People with HA receiving emicizumab were eligible for inclusion in this analysis. Clinical information was collected quarterly through participant interview and medical record review. Safety was evaluated by documenting adverse events (AEs); effectiveness was assessed by annualized bleeding rates (ABRs).
Results
At data cut‐off (31st December 2023), 257 participants were receiving emicizumab; 63 (24.5%) had FVIII inhibitors at baseline; 84.4% had severe HA. In total, 109 (42.4%) participants were
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Colorado School of Medicine, Aurora, Colorado, USA.
- Children's Mercy Hospital, Kansas City, Missouri, USA.
- American Thrombosis and Hemostasis Network, Rochester, New York, USA.
- Hemophilia of Georgia Center For Bleeding & Clotting Disorders of Emory, Emory University School of Medicine, Atlanta, Georgia, USA.
- Genentech, Inc., South San Francisco, California, USA.
- Versiti Blood Research Institute, Milwaukee, Wisconsin, USA.
ORCID-Profile: Tyler W Buckner, Michael Recht
Förderung
- Genentech, Inc
Zitieren
APA
Buckner, T. W., Carpenter, S. L., Daoud, N., Kempton, C. L., Lee, L., Malec, L., McLean, T. W., Morton, P., O'Neill, C., Staber, J. M., Wang, M., Croteau, S. E., & Recht, M. (2026). Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study. Haemophilia, 32(1), 63-70. https://doi.org/10.1111/hae.70151
Vancouver
Buckner TW, Carpenter SL, Daoud N, Kempton CL, Lee L, Malec L, et al. Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study. Haemophilia. 2026;32(1):63-70. doi:10.1111/hae.70151
BibTeX
@article{Buckner2026,
author = {Buckner, Tyler W and Carpenter, Shannon L and Daoud, Nabil and Kempton, Christine L and Lee, Lucy and Malec, Lynn and McLean, Thomas W and Morton, Paul and O'Neill, Carrie and Staber, Janice M and Wang, Michael and Croteau, Stacy E and Recht, Michael},
title = {Safety and Effectiveness of Emicizumab in People With Haemophilia A Enrolled in the ATHN 7 Haemophilia Natural History Study},
journal = {Haemophilia},
year = {2026},
volume = {32},
number = {1},
pages = {63--70},
doi = {10.1111/hae.70151}
}
EUVIMED